Literature DB >> 2839392

Phospholipid biosynthesis in mature human erythrocytes.

A Strunecká1, P Folk.   

Abstract

Mature human erythrocytes were tested for their ability to synthetize membrane phospholipids from simple precursors: [32P]-orthophosphate (32Pi), [U-14C] glycerol, [U-14C] glucose, [U-14C] serine, and [U-14C] choline. The incorporation of these labels into phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidylserine (PS), phosphatidylinositol (PI), phosphatidic acid (PA), lysophosphatidylcholine (lyso-PC), phosphatidylinositol-4-phosphate (PIP), and phosphatidylinositol-4,5-bisphosphate (PIP2) was measured. All the phospholipids tested incorporated 32Pi, glycerol, and glucose in a time dependent manner. According to the rate of 32Pi incorporation, three groups of phospholipids could be distinguished: 1) PA, PIP2, PIP, lyso-PC; 2) PI and PS; 3) PC and PE, which incorporated 5 x 10(3), 40, and 6 nmol 32Pi/mmol phospholipid per 1 h, respectively. Moreover, [U-14C] serine and [U14C] choline were found to incorporate into phospholipids, and PS-decarboxylase activity could be measured. The possibility that the observed incorporation was due to contamination with bacteria or other blood cells could be ruled out. Our results bring evidence for de novo phospholipid synthesis of human red blood cells.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2839392

Source DB:  PubMed          Journal:  Gen Physiol Biophys        ISSN: 0231-5882            Impact factor:   1.512


  2 in total

1.  Metabolomics of ADSOL (AS-1) red blood cell storage.

Authors:  John D Roback; Cassandra D Josephson; Edmund K Waller; James L Newman; Sulaiman Karatela; Karan Uppal; Dean P Jones; James C Zimring; Larry J Dumont
Journal:  Transfus Med Rev       Date:  2014-02-05

2.  Changes of molecular glycerophospholipid species in plasma and red blood cells during docosahexaenoic acid supplementation.

Authors:  Olaf Uhl; Hans Demmelmair; Mario Klingler; Berthold Koletzko
Journal:  Lipids       Date:  2013-09-17       Impact factor: 1.880

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.